CN116917338A - 包含pd1嵌合多肽的方法和组合物 - Google Patents

包含pd1嵌合多肽的方法和组合物 Download PDF

Info

Publication number
CN116917338A
CN116917338A CN202180083093.7A CN202180083093A CN116917338A CN 116917338 A CN116917338 A CN 116917338A CN 202180083093 A CN202180083093 A CN 202180083093A CN 116917338 A CN116917338 A CN 116917338A
Authority
CN
China
Prior art keywords
cells
cell
cancer
polynucleotide
effector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180083093.7A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·C·詹森
亚当·约翰逊
詹姆斯·罗瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of CN116917338A publication Critical patent/CN116917338A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180083093.7A 2020-10-09 2021-10-07 包含pd1嵌合多肽的方法和组合物 Pending CN116917338A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089752P 2020-10-09 2020-10-09
US63/089,752 2020-10-09
PCT/US2021/053971 WO2022076685A1 (en) 2020-10-09 2021-10-07 Methods and compositions comprising pd1 chimeric polypeptides

Publications (1)

Publication Number Publication Date
CN116917338A true CN116917338A (zh) 2023-10-20

Family

ID=81125513

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180083093.7A Pending CN116917338A (zh) 2020-10-09 2021-10-07 包含pd1嵌合多肽的方法和组合物

Country Status (7)

Country Link
US (1) US20230374104A1 (https=)
EP (1) EP4229079A4 (https=)
JP (1) JP2023545071A (https=)
CN (1) CN116917338A (https=)
AU (1) AU2021358524A1 (https=)
CA (1) CA3198363A1 (https=)
WO (1) WO2022076685A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3433269B1 (en) * 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
WO2018103734A1 (zh) * 2016-12-09 2018-06-14 北京中捭生物科技有限公司 嵌合抗原受体及其用途和制备方法
US11408005B2 (en) * 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
MX2020009272A (es) * 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
CN113840920A (zh) * 2019-03-14 2021-12-24 加利福尼亚大学董事会 合并的敲入筛选和在内源基因座控制下共表达的异源多肽
SG11202111031RA (en) * 2019-04-26 2021-11-29 Allogene Therapeutics Inc Rituximab-resistant chimeric antigen receptors and uses thereof

Also Published As

Publication number Publication date
EP4229079A4 (en) 2024-12-11
CA3198363A1 (en) 2022-04-14
JP2023545071A (ja) 2023-10-26
AU2021358524A1 (en) 2023-06-01
EP4229079A1 (en) 2023-08-23
AU2021358524A9 (en) 2025-03-20
WO2022076685A1 (en) 2022-04-14
US20230374104A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
JP7508516B2 (ja) 特定の組成を有する遺伝子により改変されたｔ細胞製剤
KR102624509B1 (ko) 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
US20250154465A1 (en) Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors
TW202134264A (zh) 嵌合抗原受體及其用途
TW202538050A (zh) 製備表現嵌合抗原受體的細胞之方法
KR20180021137A (ko) 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법
EP4097219A1 (en) Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors
US20230172982A1 (en) Elimination of BCMA-positive malignancies by CAR expressing NK cells
TW202019464A (zh) 針對ｓｔｅａｐ１的嵌合受體及其使用方法
TW202146644A (zh) 一種新穎的ｃｄ１６陽性自然殺手細胞及一種培養ｃｄ１６陽性自然殺手細胞的方法
US12606603B2 (en) IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy
US20230277622A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS THEREOF
CN116917338A (zh) 包含pd1嵌合多肽的方法和组合物
US20230303643A1 (en) Constitutively active tcf1 to promote memory-associated traits in car t cells
US20240352087A1 (en) T Cell Receptors (TCR) to Human Papillomavirus Proteins, Compositions, and Uses Thereof
Stringhini Direct and Indirect Harnessing of Cytotoxic CD8+ T Lymphocytes for Cancer Therapy: Adoptive Cell Therapy Versus Immunocytokines
EP4703375A1 (en) T cell receptor and use thereof
JP2023529443A (ja) 抗ｃｄ１７１キメラ抗原受容体
Valia Emerging Natural Killer Cell Immunotherapy for Acute Myeloid Leukemia
HK40110549A (zh) 用於细胞疗法的b细胞扩增方法
HK40050291B (en) Suicide module compositions and methods
HK40050291A (en) Suicide module compositions and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination